Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

59459 1490631916HCLSReviewIrelandMarch2017.pdf
Energy Boardroom

PhRMA defends Gilead's pricey Sovaldi as docs look forward to more hep C choices

11.04.2014 / Fierce Pharma

Ever since Gilead's $1,000-per-day hepatitis C pill Sovaldi stormed the market late last year, the company has been under pressure from legislators, insurers, and patient advocacy groups to lower its price. Now, doctors are weighing in on the debate.

Cover_HCLS_Ireland LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: